Clinical Trials

    Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06179888

    Phone: 346.238.2674

    Protocol Number: PRO00038209

    Description


    This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications